Adora Ndu, Pharm.D., J.D., is a seasoned biopharmaceutical executive with two decades of experience in drug development, regulatory affairs, and health policy. She is the Chief Regulatory Officer and Executive Vice President of Portfolio Strategy and Management at BridgeBio Pharma (NASDAQ: BBIO), where she oversees regulatory, quality, government affairs, and program management. She also served previously as BridgeBio’s interim Chief Legal Officer. Prior to BridgeBio, Dr. Ndu was Group Vice President at BioMarin Pharmaceutical, leading R&D strategy, scientific collaborations, and policy. Earlier in her career, she held key regulatory leadership roles at the U.S. Food and Drug Administration (FDA), including Director of Medical Policy Development at CDER, and served as a U.S. Public Health Service officer. Dr. Ndu serves on the boards of Acadia Pharmaceuticals and DBV Technologies, and actively contributes to the healthcare community through board roles at the Alliance for Regenerative Medicine, the Food and Drug Law Institute, and Howard University’s College of Pharmacy. She has received numerous honors, including awards from the U.S. Public Health Service and recognition by the Maryland Daily Record and Howard University. In 2024, she joined the Economic Club of Washington, D.C. Dr. Ndu holds a Pharm.D. from Howard University, completed a residency at Georgetown University Hospital, and earned her J.D. from the University of Maryland.